Jubilant Ingrev.

Which are the latest news on Jubilant Ingrev.?

Why is Jubilant Ingrevia Ltd falling/rising?

As of 05-Sep, Jubilant Ingrevia Ltd's stock price is at 681.15, reflecting a decline of 1.28%. The stock is underperforming its sector, has decreased trading volume, and is below key moving averages, indicating bearish trends despite some positive financial indicators.

As of 05-Sep, Jubilant Ingrevia Ltd's stock price is falling, currently at 681.15, which reflects a decrease of 8.85 or 1.28%. This decline can be attributed to several factors highlighted in the source data. <BR><BR>Firstly, the stock has underperformed its sector today by 1.09%, indicating weaker performance relative to its peers. Additionally, the trading volume has shown a significant decline, with delivery volume dropping by 65.17% compared to the 5-day average, suggesting reduced investor interest and participation. <BR><BR>Moreover, while the stock is trading above its 200-day moving average, it is below the shorter-term moving averages (5-day, 20-day, 50-day, and 100-day), which typically signals a bearish trend. The stock has also experienced a negative return of 9.40% over the past month, contrasting with a minor decline of 2.44% in the benchmark Sensex during the same period. <BR><BR>Despite some positive financial indicators, such as a low debt-to-EBITDA ratio and strong net sales, the overall market sentiment and recent performance metrics indicate that the stock is currently facing downward pressure.

Who are in the management team of Jubilant Ingrev.?

The management team of Jubilant Ingrev includes Chairman Shyam S Bhartia, Co-Chairman Hari S Bhartia, Managing Directors Rajesh Srivastava and Deepak Jain, and Whole Time Director Chandan Singh Sengar, along with several independent and non-executive directors. This diverse team brings extensive experience to the company.

The management team of Jubilant Ingrev includes the following key members:<BR><BR>1. **Shyam S Bhartia** - Chairman & Non-Executive Director<BR>2. **Hari S Bhartia** - Co-Chairman / Non-Executive Director<BR>3. **Rajesh Srivastava** - Managing Director & CEO<BR>4. **Mr. Deepak Jain** - Managing Director & CEO<BR>5. **Mr. Chandan Singh Sengar** - Whole Time Director & CEO<BR><BR>Additionally, the board includes several independent non-executive directors:<BR>- **S K Roongta**<BR>- **Sudha Pillai**<BR>- **Arun Seth**<BR>- **Pradeep Banerjee**<BR>- **Siraj Azmat Chaudhry**<BR>- **Ameeta Sonjoy**<BR><BR>There are also non-executive directors:<BR>- **Priyavrat Bhartia**<BR>- **Arjun Shanker Bhartia**<BR><BR>This diverse team brings a wealth of experience and expertise to the company.

What does Jubilant Ingrev. do?

Jubilant Ingrevia Ltd is a small-cap company in the specialty chemicals industry, incorporated in 2019, with recent quarterly net sales of ₹1,300 Cr and a net profit of ₹106 Cr as of June 2026. Key metrics include a P/E ratio of 34.00 and a market cap of ₹10,643 Cr.

Overview:<BR>Jubilant Ingrevia Ltd operates in the specialty chemicals industry and is categorized as a small-cap company.<BR><BR>History:<BR>The company was incorporated as a Public Limited Company in 2019 and changed its name from Jubilant LSI Limited to Jubilant Ingrevia Limited on October 16, 2020. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,300 Cr (Quarterly Results - Jun 2026)<BR>- Net Profit: 106 Cr (Quarterly Results - Jun 2026)<BR>- Market Cap: INR 10,643 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 34.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.72%<BR>- Debt Equity: 0.19<BR>- Return on Equity: 9.19%<BR>- Price to Book: 3.53<BR><BR>Contact Details:<BR>Details: No Company Details Available<BR>Registrar Address: Not available.

Who are the peers of the Jubilant Ingrev.?

Jubilant Ingrev.'s peers include BASF India, Fine Organic, Anupam Rasayan, Vinati Organics, Privi Speci., Alkyl Amines, Elantas Beck, Clean Science, Galaxy Surfact., and Balaji Amines. Management risk varies from excellent to below average among peers, with Privi Speci. showing the highest 1-year return at 56.88% and Jubilant Ingrev. at -6.99%.

Peers: The peers of Jubilant Ingrev. are BASF India, Fine Organic, Anupam Rasayan, Vinati Organics, Privi Speci., Alkyl Amines, Elantas Beck, Clean Science, Galaxy Surfact., and Balaji Amines.<BR><BR>Quality Snapshot: Excellent management risk is observed at Fine Organic, Clean Science, Alkyl Amines, Elantas Beck, and BASF India, while Good management risk is found at Jubilant Ingrev., Vinati Organics, Privi Speci., and Galaxy Surfact. Below Average management risk is noted for Anupam Rasayan, and Average management risk is seen at Balaji Amines. Growth is rated as Excellent for Fine Organic and Privi Speci., Average for Anupam Rasayan, and Below Average for Jubilant Ingrev., BASF India, Vinati Organics, Alkyl Amines, Elantas Beck, Clean Science, and Galaxy Surfact. Capital Structure is rated Excellent for BASF India, Fine Organic, Jubilant Ingrev., Alkyl Amines, Elantas Beck, and Clean Science, while Average is noted for Anupam Rasayan, and Below Average for Privi Speci.<BR><BR>Return Snapshot: Privi Speci. has the highest 1-year return at 56.88%, while Vinati Organics has the lowest at -22.38%, with Jubilant Ingrev.'s own 1-year return at -6.99% being higher than Vinati Organics but lower than Privi Speci. Additionally, Clean Science and Vinati Organics have negative six-month returns.

How big is Jubilant Ingrev.?

As of 31st August, Jubilant Ingrevia Ltd has a market capitalization of 10,643.00 Cr, with recent net sales of 4,650.56 Cr and a net profit of 308.63 Cr.

As of 31st August, Jubilant Ingrevia Ltd has a market capitalization of 10,643.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Jubilant Ingrevia reported Net Sales of 4,650.56 Cr and a Net Profit of 308.63 Cr.<BR><BR>The latest annual period for the balance sheet is March 2026, showing Shareholder's Funds of 3,126.22 Cr and Total Assets of 5,469.52 Cr.

Are Jubilant Ingrevia Ltd latest results good or bad?

Jubilant Ingrevia Ltd's Q1 FY27 results are strong, with a 40.91% increase in net profit and a 25.28% rise in revenue, indicating solid operational performance. However, concerns about long-term growth and high valuations suggest caution for potential investors.

Jubilant Ingrevia Ltd's latest results for Q1 FY27 can be considered good overall, showcasing significant operational improvements. The company reported a net profit of ₹105.82 crores, which reflects a robust year-on-year growth of 40.91%. Revenue also saw a substantial increase, reaching ₹1,300.27 crores, marking a 25.28% rise compared to the same quarter last year. This performance indicates strong demand dynamics and operational execution.<BR><BR>Additionally, the operating margin improved to 15.45%, up from 13.80% in the previous year, highlighting enhanced profitability. The company achieved its highest-ever quarterly revenue, which is a positive indicator of its operational capabilities.<BR><BR>However, while the quarterly results are encouraging, there are underlying concerns. The company faces structural challenges, including a negative long-term growth rate and weakening return metrics, which could affect sustainability. Investor sentiment remains cautious due to high valuations, with a price-to-earnings ratio of 37.45 times trailing earnings.<BR><BR>In summary, while the recent results are strong and demonstrate positive momentum, potential investors should consider the structural challenges and elevated valuations when evaluating the company's future prospects.

Should I buy, sell or hold Jubilant Ingrevia Ltd?

When is the next results date for Jubilant Ingrevia Ltd?

The next results date for Jubilant Ingrevia Ltd is July 22, 2026.

The next results date for Jubilant Ingrevia Ltd is scheduled for July 22, 2026.

Has Jubilant Ingrevia Ltd declared dividend?

Yes, Jubilant Ingrevia Ltd has declared a dividend of 250% (₹2.5 per share) with an ex-date of July 25, 2025. While recent total returns have been negative over shorter periods, the company has shown positive returns over longer durations.

Jubilant Ingrevia Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 250%<BR>- Amount per share: 2.5<BR>- Ex-date: Jul-25-2025<BR><BR>Dividend Yield: 0.4%<BR><BR>Total Returns by Period:<BR>In the 3-month period, the price return was -7.6%, the dividend return was 0.38%, resulting in a total return of -7.22%.<BR><BR>In the 6-month period, the price return was -14.16%, the dividend return was 0.36%, leading to a total return of -13.8%.<BR><BR>Over the 1-year period, the price return was -14.99%, the dividend return was 0.71%, culminating in a total return of -14.28%.<BR><BR>For the 2-year period, the price return was 40.7%, the dividend return was 2.08%, resulting in a total return of 42.78%.<BR><BR>In the 3-year period, the price return was 27.88%, the dividend return was 3.28%, leading to a total return of 31.16%.<BR><BR>During the 4-year period, the price return was 2.93%, the dividend return was 3.51%, resulting in a total return of 6.44%.<BR><BR>In the 5-year period, there was no price return, no dividend return, and thus a total return of 0.0%.<BR><BR>Overall, Jubilant Ingrevia Ltd has declared a significant dividend, but the recent total returns over shorter periods indicate a decline in price performance. However, over longer periods, the company has shown positive total returns, suggesting potential recovery and growth.

How has been the historical performance of Jubilant Ingrev.?

Jubilant Ingrev. has shown fluctuating financial performance, with net sales of 4,177.61 Cr in March 2025, up from 4,135.80 Cr in March 2024 but down from 4,772.69 Cr in March 2023. Key metrics like operating profit and profit after tax increased from the previous year but remained lower than in March 2023.

Answer:<BR>The historical performance of Jubilant Ingrev. shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Jubilant Ingrev. reported net sales of 4,177.61 Cr in March 2025, a slight increase from 4,135.80 Cr in March 2024, but a decrease from 4,772.69 Cr in March 2023. The total operating income followed a similar pattern, with figures of 4,177.61 Cr in March 2025 and 4,135.80 Cr in March 2024, compared to 4,772.69 Cr in March 2023. The total expenditure, excluding depreciation, was 3,658.53 Cr in March 2025, down from 3,714.68 Cr in March 2024 and 4,225.55 Cr in March 2023. Operating profit (PBDIT) for March 2025 was 556.90 Cr, an increase from 456.42 Cr in March 2024, but lower than 580.51 Cr in March 2023. Profit before tax was 343.63 Cr in March 2025, up from 267.59 Cr in March 2024, but down from 436.75 Cr in March 2023. The profit after tax for March 2025 was 251.19 Cr, an increase from 182.87 Cr in March 2024, but lower than 307.54 Cr in March 2023. The consolidated net profit for March 2025 was 251.17 Cr, compared to 182.89 Cr in March 2024 and 307.50 Cr in March 2023. The earnings per share (EPS) rose to 15.89 in March 2025 from 11.58 in March 2024, but decreased from 19.34 in March 2023. Total assets increased to 5,015.12 Cr in March 2025 from 4,719.17 Cr in March 2024, while total liabilities also rose to 5,015.12 Cr in March 2025 from 4,719.17 Cr in March 2024. The cash flow from operating activities improved to 508.00 Cr in March 2025 from 429.00 Cr in March 2024, although the net cash outflow for March 2025 was -9.00 Cr, down from a positive inflow of 6.00 Cr in March 2024.

Is Jubilant Ingrev. technically bullish or bearish?

As of November 27, 2025, Jubilant Ingrev. shows a mildly bearish trend, indicated by daily moving averages and bearish KST signals, despite some bullish momentum from weekly MACD and Bollinger Bands.

As of 27 November 2025, the technical trend for Jubilant Ingrev. has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by the daily moving averages indicating a bearish outlook and the KST showing bearish signals on both weekly and monthly time frames. While the weekly MACD and Bollinger Bands suggest some bullish momentum, the overall monthly indicators, including MACD and Dow Theory, remain mildly bearish. The stock's recent performance, with a decline of 1.51% over the past week compared to a slight gain in the Sensex, further supports the bearish sentiment.

Is Jubilant Ingrev. overvalued or undervalued?

As of November 7, 2025, Jubilant Ingrev. is considered overvalued with a valuation grade shift to expensive, reflected in its high PE Ratio of 36.66 and underperformance against the Sensex, with a year-to-date return of -19.49%.

As of 7 November 2025, the valuation grade for Jubilant Ingrev. has moved from fair to expensive, indicating a shift in its market perception. The company is currently considered overvalued. Key ratios reveal a PE Ratio of 36.66, an EV to EBITDA of 19.92, and a Price to Book Value of 3.61, which are significantly higher than many of its peers.<BR><BR>In comparison, Sun Pharma has a PE Ratio of 35.17 and an EV to EBITDA of 10.65, while Cipla stands at a more attractive PE Ratio of 22.33 and an EV to EBITDA of 5.58. This suggests that Jubilant Ingrev. is trading at a premium relative to its industry peers. Additionally, the company's stock has underperformed against the Sensex, with a year-to-date return of -19.49% compared to the Sensex's 6.50%, further reinforcing the view that it is overvalued at its current price of 662.90.

Who are the top shareholders of the Jubilant Ingrev.?

The top shareholders of Jubilant Ingrev. include promoters holding 20.63%, mutual funds with 14.1%, foreign institutional investors at 7.12%, and individual investors owning 19.13%, with Dsp Small Cap Fund being the largest public shareholder at 9.37%.

The top shareholders of Jubilant Ingrev. include a mix of promoters, mutual funds, foreign institutional investors (FIIs), and individual investors. The majority shareholders are the promoters, with the highest holding attributed to Spb Trustee Company Pl & Ss Trustee Company Pl, which holds 20.63%. <BR><BR>In terms of mutual funds, 18 schemes collectively hold 14.1% of the company. Foreign institutional investors have a stake of 7.12%, held by 116 different FIIs. The highest public shareholder is Dsp Small Cap Fund, which holds 9.37%. Additionally, individual investors collectively own 19.13% of the company.